Viamet Reports Additional Positive Interim Results of Phase 2 Study of VT-1161 in Patients with Moderate to Severe Acute Vulvovaginal Candidiasis

Study Demonstrated Strong Evidence of Clinical Antifungal Activity and a Favorable Safety Profile. Phase 2b Trial Planned for Recurrent Vulvovaginal Candidiasis in the Second Half of 2014... [more]

View complete Press Release article